Hoatlin Lab

From OpenWetWare
(Redirected from Hoatlin)
Jump to navigationJump to search

Equipped with his five senses, man explores the universe around him and calls the adventure Science. ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Projects        Team        Papers        Contact Us        Protocols        Collaborations        News        Reagent Requests        secret back door        Hoatlin Lab Twitter       



Lab News

For news, follow the Hoatlin lab Twitter


Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility. Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.

We work in Portland, Oregon at OHSU, in the Department of Biochemistry & Molecular Biology and the OHSU Knight Cancer Institute.

Bio for Maureen Hoatlin

Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU). After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers. She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002. Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway. Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.

Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.

Teaching Links

  • Our lab's Fanconi Anemia antibodies are available from Novus Biologicals and by Millipore.

PMCB Conjoint Class 2018-2019

Genetic Mechanisms Class (CON662)

Med Students Fundamentals

Biochemistry Seminar Series

Biochemistry Seminar Series and Combined Series Working Draft

Classes of the past

CONJ606/PMCB 2017-2018

Advanced Topics in Molecular Biology(BMB625)

Advanced Topics in Cancer Biology (CANB 610)

OHSU DNA Replication, Recombination and Repair (R3) Club.

Basic Wiki/OWW Links

<wikionly>

Recent changes
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

20 May 2024

     19:19  Organ/Tumor/Body-on-a-Chip - Organ on a Chip - Michele Caggioni‎‎ 45 changes history −1,748 [Sarah L. Perry‎ (45×)]
     
19:19 (cur | prev) −355 Sarah L. Perry talk contribs
     
19:12 (cur | prev) −31 Sarah L. Perry talk contribs (→‎Organ-on-a-Chip Advantages and Disadvantages)
     
19:11 (cur | prev) +8 Sarah L. Perry talk contribs (→‎Body-on-a-chip Advantages)
     
19:10 (cur | prev) −100 Sarah L. Perry talk contribs (→‎Body-on-a-chip (integration of multiple organ-on-a-chips) Advantages & Limitations)
     
19:08 (cur | prev) +4 Sarah L. Perry talk contribs (→‎Scalability of Tumor-On-A-Chip Based Drug Screening)
     
19:07 (cur | prev) −480 Sarah L. Perry talk contribs (→‎Scalability of Tumor-On-A-Chip Based Drug Screening)
     
19:02 (cur | prev) −40 Sarah L. Perry talk contribs (→‎Drug Screening)
     
18:58 (cur | prev) −14 Sarah L. Perry talk contribs (→‎Modeling)
     
18:56 (cur | prev) −134 Sarah L. Perry talk contribs (→‎Tumor Spheroid Production)
     
18:52 (cur | prev) +3 Sarah L. Perry talk contribs (→‎Tumor Spheroid Production)
 m   
18:51 (cur | prev) −1 Sarah L. Perry talk contribs (→‎Role of Microfluidics in Cancer Research)
     
18:51 (cur | prev) +9 Sarah L. Perry talk contribs (→‎Role of Microfluidics in Cancer Research)
 m   
18:50 (cur | prev) +21 Sarah L. Perry talk contribs (→‎Role of Microfluidics in Cancer Research Abroad)
     
18:46 (cur | prev) +9 Sarah L. Perry talk contribs (→‎Modeling Drug Delivery: Overview and Motivation)
     
18:45 (cur | prev) +4 Sarah L. Perry talk contribs (→‎Modeling Non-Cancerous Cell Components of the Tumor Microenvironment)
     
18:45 (cur | prev) +14 Sarah L. Perry talk contribs (→‎Modeling Non-Cancerous Cell Components of the Tumor Microenvironment)
     
18:45 (cur | prev) −4 Sarah L. Perry talk contribs (→‎Modeling the Biochemical Regulation of Cancer Proliferation)
     
18:44 (cur | prev) +12 Sarah L. Perry talk contribs (→‎Modeling the Biochemical Regulation of Cancer Proliferation)
     
18:44 (cur | prev) +8 Sarah L. Perry talk contribs (→‎Modeling the Biochemical Regulation of Cancer Proliferation)
     
18:43 (cur | prev) +14 Sarah L. Perry talk contribs (→‎Modeling the Biochemical Regulation of Cancer Proliferation)
     
18:43 (cur | prev) +10 Sarah L. Perry talk contribs (→‎Modeling Non-Cancerous Cell Components of the Tumor Microenvironment)
     
18:42 (cur | prev) +9 Sarah L. Perry talk contribs (→‎Modeling the Biochemical Regulation of Cancer Proliferation)
     
18:40 (cur | prev) −92 Sarah L. Perry talk contribs (→‎Introduction-Modeling Tumor Death: Microfluidics and Biomimetic Tumor Spheroids)
     
18:35 (cur | prev) −166 Sarah L. Perry talk contribs (→‎Introduction-Modeling Tumor Death: Microfluidics and Biomimetic Tumor Spheroids)
 m   
18:32 (cur | prev) −1 Sarah L. Perry talk contribs (→‎Kidney-on-a-Chip)
 m   
18:29 (cur | prev) 0 Sarah L. Perry talk contribs (→‎Lung-on-a-Chip)
 m   
18:28 (cur | prev) +1 Sarah L. Perry talk contribs (→‎Liver-on-a-Chip)
     
18:24 (cur | prev) −61 Sarah L. Perry talk contribs (→‎Kidney-on-a-Chip)
     
18:23 (cur | prev) −60 Sarah L. Perry talk contribs (→‎Lung-on-a-Chip)
     
18:22 (cur | prev) −62 Sarah L. Perry talk contribs (→‎Liver-on-a-Chip)
     
18:21 (cur | prev) −1 Sarah L. Perry talk contribs
     
18:20 (cur | prev) −14 Sarah L. Perry talk contribs (→‎Liver-on-a-Chip)
     
18:18 (cur | prev) +16 Sarah L. Perry talk contribs (→‎Body-on-a-chip)
     
18:17 (cur | prev) −246 Sarah L. Perry talk contribs (→‎Body-on-a-chip)
     
18:07 (cur | prev) +3 Sarah L. Perry talk contribs (→‎Body-on-a-chip)
 m   
17:52 (cur | prev) +4 Sarah L. Perry talk contribs (→‎Body-on-a-chip)
     
17:51 (cur | prev) −44 Sarah L. Perry talk contribs (→‎Organ-on-a-chip Advantages)
 m   
17:48 (cur | prev) 0 Sarah L. Perry talk contribs (→‎Organ on a Chip Advantages and Disadvantages)
     
17:47 (cur | prev) −23 Sarah L. Perry talk contribs (→‎Conventional Systems)
 m   
17:45 (cur | prev) +23 Sarah L. Perry talk contribs (→‎Conventional Systems)
     
17:44 (cur | prev) +115 Sarah L. Perry talk contribs (→‎Conventional Systems)
 m   
17:41 (cur | prev) −1 Sarah L. Perry talk contribs (→‎Limitations of Current Preclinical Techniques)
     
17:40 (cur | prev) −1 Sarah L. Perry talk contribs (→‎Limitations of Current Preclinical Techniques)
     
17:40 (cur | prev) −44 Sarah L. Perry talk contribs (→‎Introduction)
     
17:36 (cur | prev) −60 Sarah L. Perry talk contribs (→‎Introduction)
     17:32  3D Cell Culture - McLean Taggart, Emma Villares, Maximillian Marek, Scott LeBlanc, Adam Lyons and Jacob Belden‎‎ 5 changes history +142 [Sarah L. Perry‎ (5×)]
     
17:32 (cur | prev) −2 Sarah L. Perry talk contribs (→‎Air Bubbles)
     
17:31 (cur | prev) +127 Sarah L. Perry talk contribs (→‎Media Flow)
     
17:30 (cur | prev) +2 Sarah L. Perry talk contribs (→‎Media Flow)
     
17:29 (cur | prev) −29 Sarah L. Perry talk contribs (→‎Media Flow)
     
17:28 (cur | prev) +44 Sarah L. Perry talk contribs (→‎Scaffold-Based Cell Culture)

</wikionly>